by Marie Jung
The announcement of the merging of two non-profit research organizations called Calibr and TSRI sparked excitement in the field of medical research on October 20th, 2016. Dr. Peter Shultz*, the leader of both institutions, shared this insight on the new formation: “The affiliation between TSRI and Calibr is the first of its kind…we are integrating the strengths of two proven non-profit organizations, enabling TSRI to remain committed to basic biological and chemical discovery and the understanding of disease processes, while turning these insights into innovative new medicines for unmet needs ranging from cancer and degenerative disease to childhood and neglected diseases through the affiliation with Calibr…this ‘bench-to-bedside’ model has the potential to become self-sustaining, with the value we create being reinvested back into research, education and additional clinical studies.”
The new evergreen model the two organizations hope to embody represents a self-sustaining standard that sets them apart amongst the vast sea of biomedical research companies and institutions in existence today. This kind of innovation and collaboration is what makes the joint effort so interesting, fresh, and exciting.